Mucosal Immunity
Mucosal Immunity - Related Videos
02:55
Quantification of Immune Mediator Levels in Human Mucosal Lining Fluid
0 Views •
2025
This video demonstrates the quantification of immune mediator levels in neonatal human nasal mucosal lining fluid extract. An electrochemiluminescence-based multiplex assay system measures these mediators by evaluating the intensity of emitted light when they are excited.
05:31
Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
0 Views •
Cited by 4 •
2017
This protocol describes a noninvasive technique for the sampling of undisturbed mucosal lining fluid from the upper airways. It can be used to perform the quantification of in vivo levels of protein mediators, such as cytokines and chemokines, in subjects of all ages.
10:39
Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
0 Views •
Cited by 1 •
2015
There is an overall lack of knowledge about how vaccines work. Here we propose the combined use of reverse genetics and bone marrow chimeric mice to gain insight into the early host immune responses to vaccines with a special focus on dendritic cells and T cell immunity.
08:48
Immunocompetent Intestine-on-Chip Model for Analyzing Gut Mucosal Immune Responses
0 Views •
Cited by 3 •
2024
Our detailed protocol outlines the creation and use of the advanced intestine-on-chip model, which simulates human intestinal mucosa with 3D structures and various cell types, enabling in-depth analysis of immune responses and cellular functions in response to microbial colonization.
10:30
Immunocompetent Alveolus-on-Chip Model for Studying Alveolar Mucosal Immune Responses
0 Views •
Cited by 3 •
2024
Lung-on-chip models surpass traditional 2D cultures by mimicking the air-liquid interface and endothelial cell perfusion, simulating blood flow and nutrient exchange crucial for lung physiology studies. This enhances lung research relevance, offering a dynamic, physiologically accurate environment to advance the understanding and treatment of respiratory infections.
FAQs
Protection begins with epithelial cells that form a physical barrier, while mucus helps retain microbes and other particles near the surface. Antimicrobial peptides add chemical activity against invading organisms, and resident immune cells provide rapid local responses. Together, these components can restrict contact between pathogens and underlying tissues before antigen-specific immunity becomes fully engaged.
Secretory immunoglobulin A helps prevent pathogens from attaching to mucosal surfaces, limiting the first step of infection. Its activity also supports controlled interactions with beneficial microbiota rather than provoking unnecessary tissue damage. This combination allows antibody-mediated protection to operate locally, reducing microbial invasion while contributing to tolerance at barrier tissues.
Mucosal tissues encounter microbes frequently, including organisms that are harmless or beneficial. An effective response therefore needs to restrict infection without producing excessive inflammation that could damage the barrier. Coordination between rapid defenses, resident immune cells, and antigen-specific mechanisms helps balance microbial control with tolerance, preserving tissue function during continual environmental exposure.
Vaccine design can use mucosal immunity as a framework for generating protection at the surfaces where respiratory or intestinal pathogens are encountered. The relevant goal is not only systemic immune activation, but also local responses that limit pathogen attachment and support rapid barrier defense. This perspective helps guide research on vaccines tailored to mucosal sites.
The mucosal immune system must distinguish harmful microbial activity from the presence of beneficial microbiota. Secretory immunoglobulin A and other local defenses help limit pathogen attachment while supporting tolerance toward organisms that normally inhabit mucosal tissues. Studying this relationship connects immune protection with microbiome research and may clarify how barrier responses remain effective without constant inflammatory activation.
Research can examine how epithelial barriers, mucus, antimicrobial peptides, resident immune cells, and antigen-specific responses change during respiratory or intestinal disease. Comparing these protective layers may identify whether impaired pathogen exclusion, disrupted tolerance, or excessive inflammation contributes to illness. Such findings can inform studies of disease mechanisms and approaches designed to strengthen or regulate local responses.
The mechanisms of mucosal immunity suggest two broad therapeutic directions: strengthening local defenses when barrier protection is insufficient, or regulating them when immune activity becomes excessive. Candidate approaches can be evaluated by their effects on pathogen attachment, epithelial protection, microbiota tolerance, and inflammatory control. The intended outcome is improved local defense without disrupting tissue balance.